GE HealthCare has announced the renewal of its research partnership with Stanford Medicine, US, focusing on the advancement of total body positron emission tomography (PET) / computed tomography (CT) technology.
This collaboration is anticipated to find new clinical pathways and aid in improving patient outcomes via imaging solutions.
According to GE HealthCare, molecular imaging, particularly PET/CT scanners, is pivotal for precision care in various stages of the disease.
It claims to back theranostics in oncology for advanced prostate cancer, streamlines workflows in radiation oncology, and aids Alzheimer’s disease evaluation and the diagnosis of coronary artery disease through myocardial perfusion assessment.
This technology is expected to enhance diagnosis, therapeutic planning, staging, and treatment response evaluation across different care pathways.
GE HealthCare is also partnering with healthcare institutions worldwide to demonstrate how total body PET/CT imaging can address barriers that have limited the widespread adoption of PET/CT beyond oncology.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe initiative aims to utilise ultra-high sensitivity technology to transform oncology by minimising scan times and injected doses, which is particularly beneficial for vulnerable groups such as paediatric patients.
To support this research and meet clinical needs, GE HealthCare’s total body PET/CT technology is designed for ultra-low dose scans, multi-organ dynamic imaging, quick acquisitions, and dual tracer imaging.
These advancements are expected to improve diagnosis confidence and healthcare system efficiency by enhancing clinical workflows and operational efficiency.
Stanford Medicine nuclear medicine and molecular imaging division chief Dr Andrei Iagaru said: 鈥淭his technology is designed to offer a level of sensitivity and spatial resolution that can change how we design and conduct molecular imaging studies.
鈥淔or example, such technological characteristics can create opportunities to reduce anaesthesia use in paediatric imaging by dramatically shortening scan times and enable the exploration of dual-tracer studies and early diagnosis with far greater precision. Total body PET/CT technology is an ideal tool to evaluate biodistribution and dosimetry of new PET radiopharmaceuticals in our first human studies.鈥�
Recently, GE HealthCare released software combining its imaging functionalities with tools enabled by the MIM Software-developed platform to enhance imaging workflows in indications including cardiology and oncology.
